oxidopamine has been researched along with Huntington Disease in 13 studies
Oxidopamine: A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.
oxidopamine : A benzenetriol that is phenethylamine in which the hydrogens at positions 2, 4, and 5 on the phenyl ring are replaced by hydroxy groups. It occurs naturally in human urine, but is also produced as a metabolite of the drug DOPA (used for the treatment of Parkinson's disease).
Huntington Disease: A familial disorder inherited as an autosomal dominant trait and characterized by the onset of progressive CHOREA and DEMENTIA in the fourth or fifth decade of life. Common initial manifestations include paranoia; poor impulse control; DEPRESSION; HALLUCINATIONS; and DELUSIONS. Eventually intellectual impairment; loss of fine motor control; ATHETOSIS; and diffuse chorea involving axial and limb musculature develops, leading to a vegetative state within 10-15 years of disease onset. The juvenile variant has a more fulminant course including SEIZURES; ATAXIA; dementia; and chorea. (From Adams et al., Principles of Neurology, 6th ed, pp1060-4)
| Excerpt | Relevance | Reference |
|---|---|---|
| "In the BACHD model of Huntington's disease we demonstrate that the vector can be kept in a continuous ON-state for extended periods of time." | 1.48 | Therapeutic efficacy of regulable GDNF expression for Huntington's and Parkinson's disease by a high-induction, background-free "GeneSwitch" vector. ( Bähr, M; Cheng, S; Déglon, N; Konstantinova, P; Kügler, S; Liefhebber, J; Mazur, A; Pythoud, C; Raina, A; Rey, M; Streit, F; Tereshchenko, J; Vachey, G; Zimmer, V, 2018) |
| "Huntington's disease is an autosomal dominant hereditary neurodegenerative disorder characterized by severe striatal cell loss." | 1.31 | Mice transgenic for exon 1 of the Huntington's disease gene display reduced striatal sensitivity to neurotoxicity induced by dopamine and 6-hydroxydopamine. ( Brundin, P; Castilho, RF; DiFiglia, M; Hansson, O; Petersén, A; Przedborski, S; Puschban, Z; Rice, M; Romero, N; Sapp, E; Sulzer, D, 2001) |
| "Adenosine A2 receptors were labeled and visualized by autoradiography in tissue sections of the human brain using the A2-selective agonist ligand [3H](2-p-(2-carboxyethyl)phenylamino)-5'-N-carboxamidoadenosine (CGS 21680)." | 1.28 | Adenosine A2 receptors: selective localization in the human basal ganglia and alterations with disease. ( Martinez-Mir, MI; Palacios, JM; Probst, A, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (30.77) | 18.2507 |
| 2000's | 5 (38.46) | 29.6817 |
| 2010's | 4 (30.77) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, S | 1 |
| Tereshchenko, J | 1 |
| Zimmer, V | 1 |
| Vachey, G | 1 |
| Pythoud, C | 1 |
| Rey, M | 1 |
| Liefhebber, J | 1 |
| Raina, A | 1 |
| Streit, F | 1 |
| Mazur, A | 1 |
| Bähr, M | 1 |
| Konstantinova, P | 1 |
| Déglon, N | 1 |
| Kügler, S | 1 |
| Choi, ML | 1 |
| Begeti, F | 1 |
| Oh, JH | 1 |
| Lee, SY | 1 |
| O'Keeffe, GC | 1 |
| Clelland, CD | 1 |
| Tyers, P | 1 |
| Cho, ZH | 1 |
| Kim, YB | 1 |
| Barker, RA | 1 |
| Vandeputte, C | 1 |
| Taymans, JM | 1 |
| Casteels, C | 1 |
| Coun, F | 1 |
| Ni, Y | 1 |
| Van Laere, K | 1 |
| Baekelandt, V | 1 |
| Sheline, CT | 1 |
| Zhu, J | 1 |
| Zhang, W | 1 |
| Shi, C | 1 |
| Cai, AL | 1 |
| Olds, ME | 1 |
| Jacques, DB | 1 |
| Kopyov, O | 1 |
| de Lago, E | 1 |
| Fernández-Ruiz, J | 1 |
| Ortega-Gutiérrez, S | 1 |
| Cabranes, A | 1 |
| Pryce, G | 1 |
| Baker, D | 1 |
| López-Rodríguez, M | 1 |
| Ramos, JA | 1 |
| Reynolds, DS | 1 |
| Carter, RJ | 1 |
| Morton, AJ | 1 |
| Hebb, MO | 1 |
| Robertson, HA | 1 |
| Guzman, R | 1 |
| Lövblad, KO | 1 |
| Meyer, M | 1 |
| Spenger, C | 1 |
| Schroth, G | 1 |
| Widmer, HR | 1 |
| Levivier, M | 1 |
| Donaldson, D | 1 |
| Petersén, A | 1 |
| Hansson, O | 1 |
| Puschban, Z | 1 |
| Sapp, E | 1 |
| Romero, N | 1 |
| Castilho, RF | 1 |
| Sulzer, D | 1 |
| Rice, M | 1 |
| DiFiglia, M | 1 |
| Przedborski, S | 1 |
| Brundin, P | 1 |
| Burton, S | 1 |
| Daya, S | 1 |
| Potgieter, B | 1 |
| Martinez-Mir, MI | 1 |
| Probst, A | 1 |
| Palacios, JM | 1 |
13 other studies available for oxidopamine and Huntington Disease
| Article | Year |
|---|---|
Therapeutic efficacy of regulable GDNF expression for Huntington's and Parkinson's disease by a high-induction, background-free "GeneSwitch" vector.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Disease Models, Animal; Gene Expression | 2018 |
Dopaminergic manipulations and its effects on neurogenesis and motor function in a transgenic mouse model of Huntington's disease.
Topics: Animals; Brain; Corpus Striatum; Dentate Gyrus; Dopamine; Dopamine Antagonists; Female; Hippocampus; | 2014 |
Automated quantitative gait analysis in animal models of movement disorders.
Topics: Animals; Automation; Brain; Disease Models, Animal; Female; Gait; Huntington Disease; Intracranial T | 2010 |
Mitochondrial inhibitor models of Huntington's disease and Parkinson's disease induce zinc accumulation and are attenuated by inhibition of zinc neurotoxicity in vitro or in vivo.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Carrier Proteins; Cation Transport Proteins; | 2013 |
Behavioral and anatomical effects of quinolinic acid in the striatum of the hemiparkinsonian rat.
Topics: Adrenergic Agents; Amphetamine; Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; | 2005 |
UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Arachidonic Acids; Brain Chemistry; D | 2006 |
Dopamine modulates the susceptibility of striatal neurons to 3-nitropropionic acid in the rat model of Huntington's disease.
Topics: Animals; Antihypertensive Agents; Behavior, Animal; Benzazepines; Corpus Striatum; Disease Models, A | 1998 |
Motor effects and mapping of cerebral alterations in animal models of Parkinson's and Huntington's diseases.
Topics: Animals; Behavior, Animal; Brain; Brain Mapping; Corpus Striatum; Dextroamphetamine; Disease Models, | 1999 |
Imaging the rat brain on a 1.5 T clinical MR-scanner.
Topics: Animals; Artifacts; Blood-Brain Barrier; Brain; Brain Tissue Transplantation; Female; Huntington Dis | 2000 |
Metabolic changes after injection of quinolinic acid or 6-hydroxydopamine in the rat striatum: a time-course study using cytochrome oxidase and glycogene phosphorylase a histochemistry.
Topics: Animals; Autoradiography; Benzazepines; Biomarkers; Corpus Striatum; Disease Models, Animal; Dopamin | 2000 |
Mice transgenic for exon 1 of the Huntington's disease gene display reduced striatal sensitivity to neurotoxicity induced by dopamine and 6-hydroxydopamine.
Topics: Aging; Animals; Ascorbic Acid; Dopamine; Dopamine and cAMP-Regulated Phosphoprotein 32; Dose-Respons | 2001 |
Melatonin modulates apomorphine-induced rotational behaviour.
Topics: Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Hun | 1991 |
Adenosine A2 receptors: selective localization in the human basal ganglia and alterations with disease.
Topics: Adenosine; Aged; Aged, 80 and over; Animals; Basal Ganglia; Corpus Striatum; Female; Guinea Pigs; Hu | 1991 |